


Financial Results of Fiscal Year Ended June 2024

August 14, 2024

(Securities code: 7747 Prime of Tokyo Stock Exchange,
Premier of Nagoya Stock Exchange)

A decorative graphic consisting of multiple overlapping, wavy lines in shades of gray, creating a sense of movement and depth across the lower half of the page.

Contents

1. Summary of Consolidated Financial Results of FYE June 2024

2. Earnings Forecast for FYE June 2025

FYE June 2024 Main Points - 1

Revenue 107,547 Mil.Yen <Year-on-year +19.4%>

Both Medical and Device Division increased due to exchange rate fluctuation, the recovery and expansion of cases and strong demand, etc. In particular, overseas revenue increased significantly.

Achieved consolidated revenue of 100 billion yen, a significant milestone of the mid-term management plan

- **Medical Division ~Strong performance in all fields: Cardiovascular, Non-cardiovascular, and OEM business~**
 - **External environment :** Expanded and increased in the number of cases due to disappearing the impact of Covid-19(YoY+7.2%)
Increased revenue due to the exchange rate fluctuation (Yen depreciation)
 - **Cardiovascular field:** Increased in all regions, centered on PCI GW and Penetration Catheter
 - **Non-Cardiovascular field:** Increased in Peripheral vascular (US, etc.), Abdominal vascular (US/China, etc.) and Neurovascular (China, etc.)
 - **OEM business:** Increased due to new orders in US market, etc.
- **Device Division ~ Increased in Medical Components in overseas market ~**
 - **External environment :** Increased in revenue due to the exchange rate fluctuation (Yen depreciation)
 - **Medical Components business:** Increased in transactions for China
 - **Industrial Components business:** Increased in OA equipment-related transactions in the overseas market, despite a decrease in construction-related transactions in the domestic market
- **Impact of increased revenue due to exchange rate fluctuation (Yen depreciation) +6,779 Mil. Yen**

FYE June 2024 Main Points - 2

Increased in operating income due to increased in revenue despite increasing SGA

- **Gross profit: 69,053 Mil.Yen < YoY +17.4% >**
 - Increased in gross profit due to increased in revenue
- **Operating income excluding goodwill amortization, etc.: 24,168 Mil. Yen < YoY +21.2% >**
 - Increased in revenue and expenses related to sales promotion activities in domestic and overseas market
 - Increased in R&D expenses (11,662 Mil.Yen) (YoY +1,938 Mil.Yen, R&D-to-Revenue ratio 10.8 %)
 - Increased in year-end performance-based bonus due to strong performance (YoY +770 Mil.Yen)
- **Operating income: 22,135 Mil.Yen <YoY +22.8% >**
 - Increased in goodwill amortization, etc. (2,032 Mil. Yen) (YoY +128 Mil. Yen)
- **Ordinary income: 21,968 Mil.Yen <YoY +24.6% >**
 - Non-operating income: Increased in subsidy income (YoY +72 Mil.Yen) and increased in other miscellaneous income (YoY +65 Mil.Yen)
 - Non-operating expenses: Decreased in interest expenses (YoY – 82 Mil.Yen), increased in foreign exchange loss (YoY +81 Mil.Yen),
- **Net Income attributable to parent company shareholders: 15,808 Mil.Yen <YoY +20.6% >**
 - Decreased in insurance proceeds on disaster at Cebu factory (YoY -305 Mil.Yen)

Exchange rate (Unit : JPY)	US \$	EURO	CNY	BAHT
FYE June 2024	149.39	161.48	20.64	4.17
FYE June 2023	137.49	143.92	19.75	3.90

Highlights Year-on-Year

	FYE June 2023 Results		FYE June 2024 Results				(Reference) At the same exchange rate as the previous year			
	Amount (Mil.Yen)	Ratio (%)	Amount (Mil.Yen)	Ratio (%)	YoY		Amount (Mil.Yen)	Ratio (%)	YoY	
					Changes (Mil.Yen)	Changes (%)			Changes (Mil.Yen)	Changes (%)
Revenue	90,101	100.0	107,547	100.0	+17,445	+19.4	100,767	100.0	+10,666	+11.8
Gross Profit	58,832	65.3	69,053	64.2	+10,220	+17.4	64,314	63.8	+5,481	+9.3
Operating Income excluding goodwill amortization, etc.	19,934	22.1	24,168	22.5	+4,233	+21.2	20,772	20.6	+837	+4.2
Operating Income	18,030	20.0	22,135	20.6	+4,105	+22.8	18,877	18.7	+846	+4.7
Ordinary Income	17,635	19.6	21,968	20.4	+4,332	+24.6				
Net income attributable to parent company shareholders	13,106	14.5	15,808	14.7	+2,701	+20.6				
EPS (yen)	48.25	–	58.20	–	+9.95	+20.6				
EBITDA	26,742	29.7	31,856	29.6	+5,113	+19.1				

Exchange rate (Unit : JPY)	US \$	EURO	CNY	BAHT
FYE June 2024	149.39	161.48	20.64	4.17
FYE June 2023	137.49	143.92	19.75	3.90

Highlights Compared to the Plan

	FYE June 2024 Plan		FYE June 2024 Results			
	Amount (Mil.Yen)	Ratio (%)	Amount (Mil.Yen)	Ratio (%)	Compared to the plan	
					Changes (Mil.Yen)	Changes (%)
Revenue	100,353	100.0	107,547	100.0	+7,194	+7.2
Gross Profit	65,805	65.6	69,053	64.2	+3,247	+4.9
Operating Income excluding goodwill amortization, etc.	21,942	21.9	24,168	22.5	+2,226	+10.1
Operating Income	20,073	20.0	22,135	20.6	+2,062	+10.3
Ordinary Income	19,951	19.9	21,968	20.4	+2,016	+10.1
Net income attributable to parent company shareholders	14,872	14.8	15,808	14.7	+935	+6.3
EPS (yen)	54.75	–	58.20	–	+3.45	+6.3
EBITDA	29,456	29.4	31,856	29.6	+2,399	+8.1

Exchange rate (Unit : JPY)	US \$	EURO	CNY	BAHT
FYE June 2024 Results	149.39	161.48	20.64	4.17
FYE June 2024 Plan	137.50	145.00	19.50	4.10

Revenue by Segment Year-on-year

	FYE June 2023 Results		FYE June 2024 Results			
	Amount (Mil.Yen)	Ratio (%)	Amount (Mil.Yen)	Ratio (%)	Changes (Mil.Yen)	Changes (%)
Medical	78,552	87.2	95,654	88.9	+17,102	+21.8
Device	11,549	12.8	11,892	11.1	+343	+3.0
Total amount	90,101	100.0	107,547	100.0	+17,445	+19.4




(Reference)

Medical Field	85,784	95.2	103,180	95.9	+17,395	+20.3
Device Field	4,316	4.8	4,367	4.1	+50	+1.2

Operating Income by Segment Year-on-year


	FYE June 2023 Results		FYE June 2024 Results			
	Amount (Mil.Yen)	Operating margin (%)	Amount (Mil.Yen)	Operating margin (%)	Changes (Mil.Yen)	Changes (%)
Operating income excluding goodwill amortization, etc.						
Medical	18,307	23.3	24,696	25.8	+6,388	+34.9
Device	6,107	52.9	4,733	39.8	-1,374	-22.5
Erasing & Head Quarters	-4,480	–	-5,261	–	-781	+17.4
Total	19,934	22.1	24,168	22.5	+4,233	+21.2
Operating income						
Medical	16,403	20.9	22,664	23.7	+6,260	+38.2
Device	6,107	52.9	4,733	39.8	-1,374	-22.5
Erasing & Head Quarters	-4,480	–	-5,261	–	-781	+17.4
Total	18,030	20.0	22,135	20.6	+4,105	+22.8
(Reference)						
Device Division Segment Revenue	14,461	–	14,257	–	-204	-1.4

Earnings Performance by Segment




Attribution Analysis of Operating Income – 1

(Exchange Rate Fluctuations Included)




Attribution Analysis of Operating Income – 2

(Exchange Rate Fluctuations Excluded)



Situation Per Segment Division

Per Segment by Medical Division (by Geography-1)



【Revenue (YoY)】

~ Overseas revenue increased significantly due to exchange rate fluctuation, the expansion of market share following the increases of the number of cases, etc. ~

■ Japan : Increased mainly in Non-cardiovascular field

- Cardiovascular field : Increased mainly PCI GW
- Non-cardiovascular field : Increased in Gastrointestinal/Peripheral vascular products and deliveries of two "ANSUR" surgery support robots

■ Overseas : Increased in all regions due to exchange rate fluctuation, recovering and expanding cases and strong demands

● US

- Cardiovascular field : Increased in mainly in PCI GW/Penetration Catheter
- Non-cardiovascular field : Increased in Peripheral vascular products (New product "CROSSLEAD" effect) , increased in Abdominal vascular products.
- OEM Business: Increased in new orders

● Europe

- Cardiovascular field : Increased in PCI GW/Penetration Catheter

● China

- Cardiovascular field : Increased in PCI GW, Penetration Catheter and Balloon Catheter (purchased products)
- Non-cardiovascular field : Increased in all fields such as Abdominal vascular, Neurovascular and Peripheral vascular products

- OEM Business: Decreased in transactions due to customer's trends

● Other

- Cardiovascular field : Increased in PCI GW/Penetration Catheter mainly in Asia
- Non-cardiovascular field : Increased in all fields such as Abdominal, Neurovascular and Peripheral vascular mainly in Asia

【Operating Income】

Operating income increased in proportion to revenue


*In accordance with discussions with the audit corporation, 389 million yen as the full-year commission to GPO (Group Purchasing Organizations) for FYE June 2024, is recorded in a lump sum as negative sales in the 4th quarter of FYE June 2024 in US.

Per Segment by Medical Division (by Geography-2)

(Mil. Yen)		FYE June 2023 Results	FYE June 2024 Results	YoY	
				Changes	Changes (%)
Exchange rate (Yen)	USD	137.49	149.39	+11.90	+8.7
	EURO	143.92	161.48	+17.56	+12.2
	CNY	19.75	20.64	+0.89	+4.5
Total Revenue		78,552	95,654	+17,102	+21.8
Japan		13,665	14,727	+1,061	+7.8
Overseas		64,886	80,927	+16,040	+24.7
US		18,011	21,066	+3,054	+17.0
Europe		18,743	22,121	+3,378	+18.0
China		16,974	24,033	+7,058	+41.6
Other		11,156	13,705	+2,548	+22.8
Operating income		16,403	22,664	+6,260	+38.2

Per Segment by Medical Division (by Treatment-1)

【Revenue (YoY)】



Cardiovascular

- Japan : Increased mainly PCI GW
- Overseas : Increased in all regions due to exchange rate fluctuation, recovering and expanding the number of cases and strong demand
 - Increased in GW / Penetration Catheter in all regions

Non-Cardiovascular

- Japan : Increased in Gastrointestinal/Peripheral vascular products
Deliveries of two "ANSUR" surgery support robots
- Overseas : Increased in US, China and Asia
 - US : Increased in Peripheral (New product "CROSSLEAD" effect) and Abdominal vascular products
 - China : Increased in all fields such as Abdominal vascular, Neurovascular and Peripheral vascular products
 - Other : Increased in all fields such as Abdominal vascular, Neurovascular and Peripheral vascular products mainly in Asia


OEM

- Japan : Strong sales for Cardiovascular and Gastrointestinal fields
- Overseas : Increased in transactions for US though decreased in transactions for Chinese market due to customer's trends

Per Segment by Medical Division (by Treatment-2)

(Mil. Yen)		FYE June 2023 Results	FYE June 2024 Results	YoY	
				Changes	Changes(%)
Exchange rate (Yen)	USD	137.49	149.39	+11.90	+8.7
	EURO	143.92	161.48	+17.56	+12.2
	CNY	19.75	20.64	+0.89	+4.5
Total Revenue		78,552	95,654	+17,102	+21.8
	Japan	13,665	14,727	+1,061	+7.8
	Overseas	64,886	80,927	+16,040	+24.7
Cardiovascular		58,933	72,690	+13,756	+23.3
	Japan	8,236	8,443	+206	+2.5
	Overseas	50,696	64,246	+13,549	+26.7
Non-Cardiovascular		12,375	15,346	+2,971	+24.0
	Japan	3,892	4,587	+695	+17.9
	Overseas	8,482	10,758	+2,276	+26.8
OEM		7,243	7,618	+375	+5.2
	Japan	1,536	1,696	+160	+10.4
	Overseas	5,706	5,921	+214	+3.8

Per Segment by Device Division-1



【Revenue (YoY)】

Increased sales transactions for overseas market due to exchange rate fluctuation

Medical Component

- Japan : Increased in endoscope-related components transactions
- Overseas : Increased in transactions for Chinese market

Industrial Component

- Japan : Decreased in construction-related transactions
- Overseas : Increased in OA equipment-related transactions

【Operating income】

Decreased due to decreasing intersegment transactions and trends in utilization ratio although external revenue increased

Per Segment by Device Division-2

(Mil. Yen)		FYE June 2023 Results	FYE June 2024 Results	YoY	
				Changes	Changes (%)
Exchange rate (Yen)	USD	137.49	149.39	+11.90	+8.7
Total Revenue		11,549	11,892	+343	+3.0
	Japan	2,801	2,732	-68	-2.5
	Overseas	8,747	9,159	+411	+4.7
Medical Components		7,232	7,525	+292	+4.0
	Japan	981	1,082	+100	+10.2
	Overseas	6,250	6,443	+192	+3.1
Industrial Components		4,316	4,367	+50	+1.2
	Japan	1,819	1,650	-168	-9.3
	Overseas	2,496	2,716	+219	+8.8
Operating income		6,107	4,733	-1,374	-22.5
(Reference) Segment Revenue		14,461	14,257	-204	-1.4


Reference: P/L

	FYE June 2023 Results		FYE June 2024 Results			
	Amount (Mil. Yen)	Ratio (%)	Amount (Mil. Yen)	Ratio (%)	Changes (Mil. Yen)	Main comparison factors
Revenue	90,101	100.0	107,547	100.0	+17,445	•Progressed favorably mainly overseas revenue
Cost of sales	31,268	34.7	38,494	35.8	+7,225	
Gross profit	58,832	65.3	69,053	64.2	+10,220	•Increased in proportion to increasing revenue
SGA	40,802	45.3	46,917	43.6	+6,115	•Increased in expenses related to sales and R&D •Increased in performance-based bonuses
Operating income excl. goodwill amortization	19,934	22.1	24,168	22.5	+4,233	
Operating income	18,030	20.0	22,135	20.6	+4,105	
Non-operating income	308	0.3	515	0.5	+207	•Increased in subsidy income, etc.
Non-operating expense	703	0.8	683	0.6	-19	•Decreased in interest expenses
Ordinary income	17,635	19.6	21,968	20.4	+4,332	
Extraordinary income	305	0.3	21	0.0	-283	•Occurrence insurance proceeds on disaster at Cebu factory in the previous year
Extraordinary loss	197	0.2	199	0.2	+2	
Net income attributable to parent company shareholders	13,106	14.5	15,808	14.7	+2,701	
Comprehensive income	16,280	18.1	22,873	21.3	+6,592	

Reference: B/S

		FYE June 2023 Results		FYE June 2024 Results			
		Amount (Mil. Yen)	Ratio (%)	Amount (Mil. Yen)	Ratio (%)	Changes (Mil. Yen)	Main comparison factors
Assets	Current assets	90,261	52.3	94,696	49.4	+4,435	Notes and accounts receivable +2,997 Cash and deposits +773
	Fixed assets	82,383	47.7	96,917	50.6	+14,534	Investment securities +9,008 Property, plant and equipment +6,445
Total assets		172,644	100.0	191,614	100.0	+18,969	
Liabilities	Current liabilities	26,316	15.2	29,494	15.4	+3,178	Other (Advances received, etc.) +5,465 Accounts payable-other +1,994 Short-term borrowings -4,746
	Fixed liabilities	12,028	7.0	10,157	5.3	-1,870	Long-term borrowings -2,805 Deferred tax liabilities +722
Total liabilities		38,344	22.2	39,652	20.7	+1,308	
Total net assets		134,300	77.8	151,961	79.3	+17,660	Retained earnings +11,874 Foreign currency translation adjustment +6,274 Non-controlling interests -1,243
Total liabilities & net assets		172,644	100.0	191,614	100.0	+18,969	

Reference: C/F



Contents

1. Summary of Consolidated Financial Results of FYE June 2024

2. Earnings Forecast for FYE June 2025

Earnings Forecast for FYE June 2025

Aim to achieve the **consolidated revenue target of 110 billion yen** for the final year of the medium-term management plan (FYE June, 2026) **one year ahead of schedule.**

- Revenue is expected to increase to 116,737 Mil. Yen (YoY +8.5%) due to increase in overseas revenue in Medical Division
 - Cardiovascular field: Increase due to further market penetration in all regions of overseas markets
 - Non-cardiovascular field: Increase in all regions and all fields due to penetration of new products of Peripheral vascular in the U.S. market
 - OEM business: Remain almost flat due to customer's trends
 - Decrease revenue due to exchange rate fluctuation (Yen appreciation) -1,773 Mil.Yen
Revenue at the same exchange rate as the previous year YoY +10.2%

- Operating income is expected to increase double-digit growth in proportion to revenue
 - Gross profit 76,032 Mil. Yen (YoY +10.1%)
 - Improve gross profit margin (64.2%⇒65.1%)
 - Operating income 25,210 Mil. Yen (YoY+13.9%)
 - Increase in expenses for strengthening sales promotion mainly in US
 - Increase in R&D expenses (12,723 Mil. Yen, revenue ratio 10.9%)
 - Increase in QA expenses and information system expenses
 - Gross profit margin at the same exchange rate as the previous year +18.7%
 - Ordinary income 25,528 Mil. Yen(YoY +16.2%)
 - Net income attributable to parent company shareholders:18,803 Mil. Yen (YoY +18.9%)

Exchange rate (Unit : JPY)	US \$	EURO	CNY	BAHT
FYE June 2025 Plan	145.00	160.00	20.50	4.17
FYE June 2024 Results	149.39	161.48	20.64	4.17

Effect of exchange rate on operating income (Main currency)




US \$ (+ 1 yen influence) : approx.	131 Mil. Yen Increase
EURO (+ 1 yen influence) : approx.	117 Mil. Yen Increase
CNY (+ 1 yen influence) : approx.	1,199 Mil. Yen Increase
BAHT(+0.1 yen influence) : approx.	379 Mil. Yen Decrease

Earnings Forecast for FYE June 2025

	FYE June 2024 Results		FYE June 2025 Plan				(Reference) At the same exchange rate as the previous year			
	Amount (Mil.Yen)	Ratio (%)	Amount (Mil.Yen)	Ratio(%)	YoY		Amount (Mil.Yen)	Ratio (%)	YoY	
					Changes (Mil.Yen)	Changes (%)			Changes (Mil.Yen)	Changes (%)
Revenue	107,547	100.0	116,737	100.0	+9,190	+8.5	118,510	100.0	+10,963	+10.2
Gross profit	69,053	64.2	76,032	65.1	+6,979	+10.1	77,507	65.4	+8,454	+12.2
Operating income excluding goodwill amortization, etc.	24,168	22.5	27,170	23.3	+3,002	+12.4	28,279	23.9	+4,111	+17.0
Operating income	22,135	20.6	25,210	21.6	+3,074	+13.9	26,283	22.2	+4,147	+18.7
Ordinary income	21,968	20.4	25,528	21.9	+3,560	+16.2				
Net income attributable to parent company shareholders	15,808	14.7	18,803	16.1	+2,995	+18.9				
EPS (Yen)	58.20	–	69.22	–	+11.02	+18.9				
EBITDA	31,856	29.6	35,391	30.3	+3,535	+11.1				

Exchange rate (Unit : JPY)	US\$	EURO	CNY	BAHT
FYE June 2025 Plan	145.00	160.00	20.50	4.17
FYE June 2024 Results	149.39	161.48	20.64	4.17


Earnings Performance by Segment



* : Due to organizational expansion, attribution of administrative costs for some overseas subsidiaries has been changed from Medical and Device Business segment proportionally to Corporate segment from FYE June 2025. (FY25/6: Medical division -1,875 Device division -452 ⇒ Elimination/Headquarters +2,327)


Attribution Analysis of Operating Income – 1

(Exchange Rate Fluctuations Included)



Attribution Analysis of Operating Income - 2

(Exchange Rate Fluctuations Excluded)




R&D Expenses

Continuing aggressive investment in both new and existing projects

<Criteria : R&D to Revenue ratio upper limit 12%>


Since high percentage of revenue is foreign currency denominated and the majority of R&D expenses is yen denominated, the ratio tends to be low



Results and Plan for Equipment Installation

Expansion of R&D building and expansion of overseas factory bases for future production increase are expected to be completed to a certain extent.

Main investment matter (More than 100 Mil. Yen) (Mil. Yen)	FYE June 2021 Results	FYE June 2022 Results	FYE June 2023 Results	FYE June 2024 Results	FYE June 2025 (Plan)
Expansion of New Building in Seto			3,559	4,224	
Expansion of Shizuoka R&D Center				776	1,322
Expansion of Thailand factory		869	1,213	717	
Expansion of Hanoi factory			1,396	1,114	1,495
Expansion of Cebu factory	965	1,579	749		
Introduction of SAP	1,125				



Caution Regarding Information Presented

All forward looking statements contained herein, including revenue forecasts, outlooks, and strategic plans, are based on the best currently available data; however, risk and uncertainty are involved in these statements.

Please note that actual results may differ greatly from plans presented here.

【 IR contact 】

Asahi Intecc Co., Ltd.
corporate strategic office

TEL 0561-48-5551

URL <http://www.asahi-intecc.co.jp/en/>